ID: ALA304605

Max Phase: Preclinical

Molecular Formula: C28H27Cl2N3O

Molecular Weight: 492.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2

Standard InChI:  InChI=1S/C28H27Cl2N3O/c29-25-8-5-9-26(27(25)30)33-16-14-32(15-17-33)13-4-3-12-31-28(34)21-10-11-24-22(19-21)18-20-6-1-2-7-23(20)24/h1-11,19H,12-18H2,(H,31,34)/b4-3+

Standard InChI Key:  ZCTVOGWWMHRQLN-ONEGZZNKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.45

Molecular Weight (Monoisotopic): 491.1531

AlogP: 5.67

#Rotatable Bonds: 6

Polar Surface Area: 35.58

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 6.40

CX LogP: 6.31

CX LogD: 6.26

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.35

Np Likeness Score: -1.04

References

1. Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR..  (2003)  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.,  13  (13): [PMID:12798330] [10.1016/s0960-894x(03)00389-5]

2. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH..  (2005)  Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.,  48  (3): [PMID:15689168] [10.1021/jm049465g]

3. Newman AH, Grundt P, Nader MA..  (2005)  Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.,  48  (11): [PMID:15916415] [10.1021/jm040190e]

4. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH..  (2007)  Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.,  50  (17): [PMID:17672446] [10.1021/jm0704200]

5. Li A, Mishra Y, Malik M, Wang Q, Li S, Taylor M, Reichert DE, Luedtke RR, Mach RH..  (2013)  Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.,  21  (11): [PMID:23618707] [10.1016/j.bmc.2013.03.074]

Source

Source(1):

• Scientific Literature